Maen Abdelrahim, MD, PhD, B Pharm

Assistant Professor of Medicine in Oncology, Institute for Academic Medicine
Director, Cockrell Center for Advanced Therapeutics; Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Abdelrahim completed pharmacy training followed by graduate work in the field of pharmacology and toxicology. Upon completion of his graduate work, clinical training as a medical oncologist fueled his motivation and expertise in the field of anticancer drug discovery.

His translational research is focusing on the discovery and development of new anticancer drugs. He has identified for the first time a new structural class of compounds that can target selective transcription factor called Sp proteins. Transcription factors are now recognized as targets for the development of new anticancer drugs. 

Description of Research

  • Targeted therapy in GI cancer
  • Immunotherapy
  • T cell therapy 

Dr. Abdelrahim's research has pinpointed few compounds that inhibit tumor growth and angiogenesis in-part by inducing proteasome-dependent degradation of selected Sp proteins in cancer cells and tumors. The lead compound of this class (Tolfenamic acid) has reached Phase I Clinical Trial to treat patients with advanced and metastatic pancreatic cancer in combination with gemcitabine and radiation therapy. Dr. Abdelrahim has a patent application submitted for the new use of these compounds in GI cancers. In prior research, he was the first to find that Sp4 protein is over expressed in GI cancers including pancreatic cancer and that the role of Sp4 can be equally important as Sp1 in some type of GI cancers.

Researchers in cancer have the ultimate responsibility of taking their findings to the clinic which is described as translational research. By seeing GI cancer patients in his practice, collaborating with translational scientist in the lab and conducting and directing clinical trials, Dr. Abdelrahim hopes to continue to fuel the translational research cycle from lab to clinic and back to the lab.

 

Areas Of Expertise

Clinical trials Gastrointestinal cancer Clinical research Translation research
Education & Training

Internship, Baylor College of Medicine
Residency
Fellow, Duke University Medical Center
MD, Texas A&M Health Science Center College of Medicine
PhD, Texas A&M University
B Pharm, Isra University
Publications

Specificity protein transcription factors and cancer: Opportunities for drug development
Safe, S, Abbruzzese, J, Abdelrahim, M & Hedrick, E 2018, Cancer Prevention Research, vol. 11, no. 7, pp. 371-381. DOI: 10.1158/1940-6207.CAPR-17-0407

Renal complications of primary myelofibrosis
Strati, P, Glass, WF, Abdelrahim, M, Selamet, U, Tchakarov, A, Workeneh, BT, Verstovsek, S & Abudayyeh, A 2018, Leukemia and Lymphoma, pp. 1-4. DOI: 10.1080/10428194.2018.1474525

Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam
Ertem, FU, Zhang, W, Chang, K, Mohaiza Dashwood, W, Rajendran, P, Sun, D, Abudayyeh, A, Vilar, E, Abdelrahim, M & Dashwood, RH 2017, International Journal of Cancer, vol. 140, no. 2, pp. 460-468. DOI: 10.1002/ijc.30458

Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury
Oliver, N, Luong, T, Tchakarov, A, Abdelrahim, M, Mulanovich, VE, Kontoyiannis, DP, Jones, R, Kebriaei, P, Samuels, JA, Glass, JW & Abudayyeh, A 2016, Bone Marrow Transplantation, vol. 51, no. 10, pp. 1301-1304. DOI: 10.1038/bmt.2016.120

Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients
Abudayyeh, A, Hamdi, A, Lin, H, Abdelrahim, M, Rondon, G, Andersson, BS, Afrough, A, Martinez, CS, Tarrand, JJ, Kontoyiannis, DP, Marin, D, Gaber, AO, Salahudeen, A, Oran, B, Chemaly, RF, Olson, A, Jones, R, Popat, U, Champlin, RE, Shpall, EJ, Winkelmayer, WC & Rezvani, K 2016, American Journal of Transplantation. DOI: 10.1111/ajt.13635

Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients
Abudayyeh, A, Hamdi, A, Abdelrahim, M, Lin, H, Page, VD, Rondon, G, Andersson, BS, Afrough, A, Martinez, CS, Tarrand, JJ, Kontoyiannis, DP, Marin, D, Gaber, AO, Oran, B, Chemaly, RF, Ahmed, S, Abudayyeh, I, Olson, A, Jones, R, Popat, U, Champlin, RE, Shpall, EJ & Rezvani, K 2016, Transplant Infectious Disease. DOI: 10.1111/tid.12632

Targeted Therapy in Solid Tumors: Colorectal Cancer
Abdelrahim, M, Kopetz, S & Menter, DG 2015, . in Targeted Therapy in Translational Cancer Research. Wiley, pp. 193-204. DOI: 10.1002/9781118468678.ch20

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines
Naing, A, Dalal, S, Abdelrahim, M, Wheler, JJ, Hess, KC, Fu, S, Hong, DS, Janku, F, Falchook, GS, Ilustre, A, Ouyang, F & Kurzrock, R 2015, Supportive Care in Cancer, vol. 23, no. 9, pp. 2649-2654. DOI: 10.1007/s00520-015-2625-9

Obstructive renal disease in cancer patients
Abudayyeh, A & Abdelrahim, M 2015, . in Onconephrology: Cancer, Chemotherapy and the Kidney. Springer New York, pp. 309-317. DOI: 10.1007/978-1-4939-2659-6_15

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Rajasekaran, A, Ngo, T-T, Abdelrahim, M, Glass, W, Podoll, A, Verstovsek, S & Abudayyeh, A 2015, BMC Nephrology, vol. 16, pp. 121. DOI: 10.1186/s12882-015-0121-6

Current Strategies for Prevention and Management of Stem Cell Transplant-Related Urinary Tract and Voiding Dysfunction
Abudayyeh, A & Abdelrahim, M 2015, Current Bladder Dysfunction Reports, vol. 10, no. 2, pp. 109-117. DOI: 10.1007/s11884-015-0289-4

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma
Hedrick, E, Lee, S-O, Kim, G, Abdelrahim, M, Jin, U-H, Safe, SH & Abudayyeh, A 2015, PLoS ONE, vol. 10, no. 6, pp. e0128308. DOI: 10.1371/journal.pone.0128308

Membranous nephropathy in autologous hematopoietic stem cell transplant: Autologous graft-versus-host disease or autoimmunity induction?
Abudayyeh, A, Truong, LD, Beck, LH, Weber, DM, Rezvani, K & Abdelrahim, M 2015, Clinical Kidney Journal, vol. 8, no. 4, pp. 440-444. DOI: 10.1093/ckj/sfv036

Phase i trial of valproic acid and lenalidomide in patients with advanced cancer
Bilen, MA, Fu, S, Falchook, GS, Ng, CS, Wheler, JJ, Abdelrahim, M, Erguvan-Dogan, B, Hong, DS, Tsimberidou, AM, Kurzrock, R & Naing, A 2015, Cancer Chemotherapy and Pharmacology, vol. 75, no. 4, pp. 869-874. DOI: 10.1007/s00280-015-2695-x

Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors
Nair, V, Pathi, S, Jutooru, I, Sreevalsan, S, Basha, R, Abdelrahim, M, Samudio, I & Safe, SH 2013, Carcinogenesis, vol. 34, no. 12, pp. 2870-2879. DOI: 10.1093/carcin/bgt231

TAS-106: Preclinical, clinical and beyond
Abdelrahim, M, Matsuda, A & Naing, A 2013, Oncology, vol. 85, no. 6, pp. 356-363. DOI: 10.1159/000356571

Fluid and Electrolyte Abnormalities in Patients with Cancer
Abudayyeh, A, Abdelrahim, M & Salahudeen, A 2013, . in Renal Disease in Cancer Patients. Elsevier, pp. 167-182. DOI: 10.1016/B978-0-12-415948-8.00011-8

Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer
Sankpal, UT, Abdelrahim, M, Connelly, SF, Lee, CM, Madero-Visbal, R, Colon, J, Smith, J, Safe, SH, Maliakal, P & Basha, R 2012, Prostate, vol. 72, no. 15, pp. 1648-1658. DOI: 10.1002/pros.22518

Environmental factors in causing human cancers: Emphasis on tumorigenesis
Sankpal, UT, Pius, H, Khan, M, Shukoor, MI, Maliakal, P, Lee, CM, Abdelrahim, M, Connelly, SF & Basha, R 2012, Tumor Biology, vol. 33, no. 5, pp. 1265-1274. DOI: 10.1007/s13277-012-0413-4

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats
Maliakal, P, Abdelrahim, M, Sankpal, UT, Maliakal, C, Baker, CH, Safe, SH, Herrera Garza, JL, Abudayyeh, A, Kaja, S & Basha, R 2012, Investigational New Drugs, vol. 30, no. 3, pp. 853-861. DOI: 10.1007/s10637-010-9622-0